View Item 

Show simple item record

Citrullination of Epithelial Neutrophil–Activating Peptide 78/CXCL5 Results in Conversion From a Non–Monocyte‐Recruiting Chemokine to a Monocyte‐Recruiting Chemokine
dc.contributor.authorYoshida, Kenen_US
dc.contributor.authorKorchynskyi, Olexandren_US
dc.contributor.authorTak, Paul P.en_US
dc.contributor.authorIsozaki, Takeoen_US
dc.contributor.authorRuth, Jeffrey H.en_US
dc.contributor.authorCampbell, Phillip L.en_US
dc.contributor.authorBaeten, Dominique L.en_US
dc.contributor.authorGerlag, Danielle M.en_US
dc.contributor.authorAmin, M. Asifen_US
dc.contributor.authorKoch, Alisa E.en_US
dc.date.accessioned2014-10-07T16:09:10Z
dc.date.availableWITHHELD_13_MONTHSen_US
dc.date.available2014-10-07T16:09:10Z
dc.date.issued2014-10en_US
dc.identifier.citationYoshida, Ken; Korchynskyi, Olexandr; Tak, Paul P.; Isozaki, Takeo; Ruth, Jeffrey H.; Campbell, Phillip L.; Baeten, Dominique L.; Gerlag, Danielle M.; Amin, M. Asif; Koch, Alisa E. (2014). "Citrullination of Epithelial Neutrophil–Activating Peptide 78/CXCL5 Results in Conversion From a Non–Monocyte‐Recruiting Chemokine to a Monocyte‐Recruiting Chemokine." Arthritis & Rheumatology 66(10): 2716-2727.en_US
dc.identifier.issn2326-5191en_US
dc.identifier.issn2326-5205en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/108594
dc.publisherWiley Periodicals, Inc.en_US
dc.titleCitrullination of Epithelial Neutrophil–Activating Peptide 78/CXCL5 Results in Conversion From a Non–Monocyte‐Recruiting Chemokine to a Monocyte‐Recruiting Chemokineen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelRheumatologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/108594/1/art38750.pdf
dc.identifier.doi10.1002/art.38750en_US
dc.identifier.sourceArthritis & Rheumatologyen_US
dc.identifier.citedreferenceHatano Y, Kasama T, Iwabuchi H, Hanaoka R, Takeuchi HT, Jing L, et al. Macrophage inflammatory protein 1 α expression by synovial fluid neutrophils in rheumatoid arthritis. Ann Rheum Dis 1999; 58: 297 – 302.en_US
dc.identifier.citedreferenceLoos T, Mortier A, Gouwy M, Ronsse I, Put W, Lenaerts JP, et al. Citrullination of CXCL10 and CXCL11 by peptidylarginine deiminase: a naturally occurring posttranslational modification of chemokines and new dimension of immunoregulation. Blood 2008; 112: 2648 – 56.en_US
dc.identifier.citedreferenceStruyf S, Noppen S, Loos T, Mortier A, Gouwy M, Verbeke H, et al. Citrullination of CXCL12 differentially reduces CXCR4 and CXCR7 binding with loss of inflammatory and anti‐HIV‐1 activity via CXCR4. J Immunol 2009; 182: 666 – 74.en_US
dc.identifier.citedreferenceChang X, Zhao Y, Sun S, Zhang Y, Zhu Y. The expression of PADI4 in synovium of rheumatoid arthritis. Rheumatol Int 2009; 29: 1411 – 6.en_US
dc.identifier.citedreferenceKoch AE, Kunkel SL, Harlow LA, Johnson B, Evanoff HL, Haines GK, et al. Enhanced production of monocyte chemoattractant protein‐1 in rheumatoid arthritis. J Clin Invest 1992; 90: 772 – 9.en_US
dc.identifier.citedreferenceKoch AE, Kunkel SL, Harlow LA, Mazarakis DD, Haines GK, Burdick MD, et al. Macrophage inflammatory protein‐1 α: a novel chemotactic cytokine for macrophages in rheumatoid arthritis. J Clin Invest 1994; 93: 921 – 8.en_US
dc.identifier.citedreferenceAkahoshi T, Wada C, Endo H, Hirota K, Hosaka S, Takagishi K, et al. Expression of monocyte chemotactic and activating factor in rheumatoid arthritis: regulation of its production in synovial cells by interleukin‐1 and tumor necrosis factor. Arthritis Rheum 1993; 36: 762 – 71.en_US
dc.identifier.citedreferencePeichl P, Ceska M, Effenberger F, Haberhauer G, Broell H, Lindley IJ. Presence of NAP‐1/IL‐8 in synovial fluids indicates a possible pathogenic role in rheumatoid arthritis. Scand J Immunol 1991; 34: 333 – 9.en_US
dc.identifier.citedreferenceMortier A, Gouwy M, Van Damme J, Proost P. Effect of posttranslational processing on the in vitro and in vivo activity of chemokines. Exp Cell Res 2011; 317: 642 – 54.en_US
dc.identifier.citedreferenceMortier A, Loos T, Gouwy M, Ronsse I, Van Damme J, Proost P. Posttranslational modification of the NH2‐terminal region of CXCL5 by proteases or peptidylarginine deiminases (PAD) differently affects its biological activity. J Biol Chem 2010; 285: 29750 – 9.en_US
dc.identifier.citedreferenceStrieter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, Kasper J, et al. The functional role of the ELR motif in CXC chemokine‐mediated angiogenesis. J Biol Chem 1995; 270: 27348 – 57.en_US
dc.identifier.citedreferenceKoch AE, Volin MV, Woods JM, Kunkel SL, Connors MA, Harlow LA, et al. Regulation of angiogenesis by the C‐X‐C chemokines interleukin‐8 and epithelial neutrophil activating peptide 78 in the rheumatoid joint. Arthritis Rheum 2001; 44: 31 – 40.en_US
dc.identifier.citedreferenceHolmes WE, Lee J, Kuang WJ, Rice GC, Wood WI. Structure and functional expression of a human interleukin‐8 receptor. Science 1991; 253: 1278 – 80.en_US
dc.identifier.citedreferenceMurphy PM, Tiffany HL. Cloning of complementary DNA encoding a functional human interleukin‐8 receptor. Science 1991; 253: 1280 – 3.en_US
dc.identifier.citedreferencePersson T, Monsef N, Andersson P, Bjartell A, Malm J, Calafat J, et al. Expression of the neutrophil‐activating CXC chemokine ENA‐78/CXCL5 by human eosinophils. Clin Exp Allergy 2003; 33: 531 – 7.en_US
dc.identifier.citedreferenceHoruk R. Chemokine receptors. Cytokine Growth Factor Rev 2001; 12: 313 – 35.en_US
dc.identifier.citedreferenceChapman RW, Phillips JE, Hipkin RW, Curran AK, Lundell D, Fine JS. CXCR2 antagonists for the treatment of pulmonary disease. Pharmacol Ther 2009; 121: 55 – 68.en_US
dc.identifier.citedreferenceBrowning DD, Diehl WC, Hsu MH, Schraufstatter IU, Ye RD. Autocrine regulation of interleukin‐8 production in human monocytes. Am J Physiol Lung Cell Mol Physiol 2000; 279: L1129 – 36.en_US
dc.identifier.citedreferenceLudwig A, Petersen F, Zahn S, Gotze O, Schroder JM, Flad HD, et al. The CXC‐chemokine neutrophil‐activating peptide‐2 induces two distinct optima of neutrophil chemotaxis by differential interaction with interleukin‐8 receptors CXCR‐1 and CXCR‐2. Blood 1997; 90: 4588 – 97.en_US
dc.identifier.citedreferenceMurphy PM, Baggiolini M, Charo IF, Hebert CA, Horuk R, Matsushima K, et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000; 52: 145 – 76.en_US
dc.identifier.citedreferenceSnir O, Rieck M, Gebe JA, Yue BB, Rawlings CA, Nepom G, et al. Identification and functional characterization of T cells reactive to citrullinated vimentin in HLA–DRB1*0401–positive humanized mice and rheumatoid arthritis patients. Arthritis Rheum 2011; 63: 2873 – 83.en_US
dc.identifier.citedreferenceFan LY, He DY, Wang Q, Zong M, Zhang H, Yang L, et al. Citrullinated vimentin stimulates proliferation, pro‐inflammatory cytokine secretion, and PADI4 and RANKL expression of fibroblast‐like synoviocytes in rheumatoid arthritis. Scand J Rheumatol 2012; 41: 354 – 8.en_US
dc.identifier.citedreferenceLiddiard K, Rosas M, Davies LC, Jones SA, Taylor PR. Macrophage heterogeneity and acute inflammation. Eur J Immunol 2011; 41: 2503 – 8.en_US
dc.identifier.citedreferenceTak PP, Bresnihan B. The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis. Arthritis Rheum 2000; 43: 2619 – 33.en_US
dc.identifier.citedreferenceVan Venrooij WJ, van Beers JJ, Pruijn GJ. Anti‐CCP antibodies: the past, the present and the future. Nat Rev Rheumatol 2011; 7: 391 – 8.en_US
dc.identifier.citedreferenceSchellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis‐specific autoantibodies. J Clin Invest 1998; 101: 273 – 81.en_US
dc.identifier.citedreferenceSebbag M, Moinard N, Auger I, Clavel C, Arnaud J, Nogueira L, et al. Epitopes of human fibrin recognized by the rheumatoid arthritis‐specific autoantibodies to citrullinated proteins. Eur J Immunol 2006; 36: 2250 – 63.en_US
dc.identifier.citedreferenceSuzuki A, Yamada R, Yamamoto K. Citrullination by peptidylarginine deiminase in rheumatoid arthritis. Ann N Y Acad Sci 2007; 1108: 323 – 39.en_US
dc.identifier.citedreferenceMangat P, Wegner N, Venables PJ, Potempa J. Bacterial and human peptidylarginine deiminases: targets for inhibiting the autoimmune response in rheumatoid arthritis? Arthritis Res Ther 2010; 12: 209.en_US
dc.identifier.citedreferenceSzekanecz Z, Kim J, Koch AE. Chemokines and chemokine receptors in rheumatoid arthritis. Semin Immunol 2003; 15: 15 – 21.en_US
dc.identifier.citedreferenceHaringman JJ, Ludikhuize J, Tak PP. Chemokines in joint disease: the key to inflammation? Ann Rheum Dis 2004; 63: 1186 – 94.en_US
dc.identifier.citedreferenceZlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000; 12: 121 – 7.en_US
dc.identifier.citedreferenceWalz A, Burgener R, Car B, Baggiolini M, Kunkel SL, Strieter RM. Structure and neutrophil‐activating properties of a novel inflammatory peptide (ENA‐78) with homology to interleukin 8. J Exp Med 1991; 174: 1355 – 62.en_US
dc.identifier.citedreferenceKoch AE, Kunkel SL, Harlow LA, Mazarakis DD, Haines GK, Burdick MD, et al. Epithelial neutrophil activating peptide‐78: a novel chemotactic cytokine for neutrophils in arthritis. J Clin Invest 1994; 94: 1012 – 8.en_US
dc.identifier.citedreferenceHalloran MM, Woods JM, Strieter RM, Szekanecz Z, Volin MV, Hosaka S, et al. The role of an epithelial neutrophil‐activating peptide‐78‐like protein in rat adjuvant‐induced arthritis. J Immunol 1999; 162: 7492 – 500.en_US
dc.identifier.citedreferenceKinloch A, Tatzer V, Wait R, Peston D, Lundberg K, Donatien P, et al. Identification of citrullinated α‐enolase as a candidate autoantigen in rheumatoid arthritis. Arthritis Res Ther 2005; 7: R1421 – 9.en_US
dc.identifier.citedreferenceVan Steendam K, Tilleman K, De Ceuleneer M, De Keyser F, Elewaut D, Deforce D. Citrullinated vimentin as an important antigen in immune complexes from synovial fluid of rheumatoid arthritis patients with antibodies against citrullinated proteins. Arthritis Res Ther 2010; 12: R132.en_US
dc.identifier.citedreferenceVossenaar ER, Smeets TJ, Kraan MC, Raats JM, van Venrooij WJ, Tak PP. The presence of citrullinated proteins is not specific for rheumatoid synovial tissue. Arthritis Rheum 2004; 50: 3485 – 94.en_US
dc.identifier.citedreferenceFoulquier C, Sebbag M, Clavel C, Chapuy‐Regaud S, Al Badine R, Mechin MC, et al. Peptidyl arginine deiminase type 2 (PAD‐2) and PAD‐4 but not PAD‐1, PAD‐3, and PAD‐6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation. Arthritis Rheum 2007; 56: 3541 – 53.en_US
dc.identifier.citedreferenceKorchynskyi O, ten Dijke P. Identification and functional characterization of distinct critically important bone morphogenetic protein‐specific response elements in the Id1 promoter. J Biol Chem 2002; 277: 4883 – 91.en_US
dc.identifier.citedreferenceSenshu T, Sato T, Inoue T, Akiyama K, Asaga H. Detection of citrulline residues in deiminated proteins on polyvinylidene difluoride membrane. Anal Biochem 1992; 203: 94 – 100.en_US
dc.identifier.citedreferenceTsuji Y, Akiyama M, Arita K, Senshu T, Shimizu H. Changing pattern of deiminated proteins in developing human epidermis. J Invest Dermatol 2003; 120: 817 – 22.en_US
dc.identifier.citedreferenceKubota K, Yoneyama‐Takazawa T, Ichikawa K. Determination of sites citrullinated by peptidylarginine deiminase using 18O stable isotope labeling and mass spectrometry. Rapid Commun Mass Spectrom 2005; 19: 683 – 8.en_US
dc.identifier.citedreferenceRuth JH, Haas CS, Park CC, Amin MA, Martinez RJ, Haines GK III, et al. CXCL16‐mediated cell recruitment to rheumatoid arthritis synovial tissue and murine lymph nodes is dependent upon the MAPK pathway. Arthritis Rheum 2006; 54: 765 – 78.en_US
dc.identifier.citedreferenceRuth JH, Arendt MD, Amin MA, Ahmed S, Marotte H, Rabquer BJ, et al. Expression and function of CXCL16 in a novel model of gout. Arthritis Rheum 2010; 62: 2536 – 44.en_US
dc.identifier.citedreferenceKoch AE, Burrows JC, Marder R, Domer PH, Leibovich SJ. Reactivity of human tissues with monoclonal antibodies to myeloid activation and differentiation antigens: an immunohistochemical study. Pathobiology 1990; 58: 241 – 8.en_US
dc.identifier.citedreferencePrevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty‐eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44 – 8.en_US
dc.identifier.citedreferenceWuyts A, Govaerts C, Struyf S, Lenaerts JP, Put W, Conings R, et al. Isolation of the CXC chemokines ENA‐78, GRO α and GRO γ from tumor cells and leukocytes reveals NH2‐terminal heterogeneity: functional comparison of different natural isoforms. Eur J Biochem 1999; 260: 421 – 9.en_US
dc.identifier.citedreferenceGerszten RE, Garcia‐Zepeda EA, Lim YC, Yoshida M, Ding HA, Gimbrone MA, et al. MCP‐1 and IL‐8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 1999; 398: 718 – 23.en_US
dc.identifier.citedreferenceProost P, Loos T, Mortier A, Schutyser E, Gouwy M, Noppen S, et al. Citrullination of CXCL8 by peptidylarginine deiminase alters receptor usage, prevents proteolysis, and dampens tissue inflammation. J Exp Med 2008; 205: 2085 – 97.en_US
dc.identifier.citedreferenceLoos T, Opdenakker G, Van Damme J, Proost P. Citrullination of CXCL8 increases this chemokine's ability to mobilize neutrophils into the blood circulation. Haematologica 2009; 94: 1346 – 53.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
art38750.pdf
Size:
709.6KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.